OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023

15 Mar 2023
www.biospace.com
Phase 2AACRImmunotherapy
SOUTHLAKE, Texas--(BUSINESS WIRE)-- OncoNano Medicine, Inc. today announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida. Presentation Overview: TITLE: Improved tolerability and tumor specific delivery of a therapeutic bispecific T cell engager using a pH-sensitive nanoparticle platform PRESENTER: Qingtai Su, Ph.D. DATE: April 16, 2023 TIME: 1:30 – 5:00 PM ET SECTION and PRESENTATION NUMBER: Poster Section 30, No. 815 TITLE: Encapsulation of IL-12 with an ultra pH-sensitive nanoparticle platform improves tolerability and promotes antitumor response in mice PRESENTER: Tian Zhao, Ph.D. DATE: April 16, 2023 TIME: 1:30 – 5:00 PM ET SECTION and PRESENTATION NUMBER: Poster Section 34, No. LB001 TITLE: ONM-501, a dual-activating polyvalent STING agonistpolyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety pro > PRESENTER: Zirong Chen, Ph.D. DATE: April 18, 2023 TIME: 1:30 – 5:00 PM ET SECTION and PRESENTATION NUMBER: Poster Section 34, No. LB245 About OncoNano Medicine OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image guided surgery and a platform of immune-oncology therapeutics that activate and guide the body’s immune system to target cancer. OncoNano’s lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ONBOARD platform, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNano’s second development program, is a next generation STING (STimulator of INterferon Genes) agonistSTING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.